amezosvatein (CRV-101)

About Curevo Vaccine

Curevo Vaccine is a private, clinical-stage biotech founded in 2020 and based in Seattle, USA, developing adjuvanted subunit vaccines as an alternative to mRNA and live-attenuated platforms. The company's lead program, amezosvatein, has generated Phase 2 data showing non-inferior immunogenicity to the market leader Shingrix® for shingles, alongside a significantly improved tolerability profile. Curevo's strategy is to address vaccine hesitancy and accessibility issues, with plans to expand development into immunocompromised populations for chickenpox. The company is currently pre-revenue, advancing its lead candidate toward Phase 3 trials.

About Curevo Vaccine

Curevo Vaccine is a private, clinical-stage biotech founded in 2020 and based in Seattle, USA, developing adjuvanted subunit vaccines as an alternative to mRNA and live-attenuated platforms. The company's lead program, amezosvatein, has generated Phase 2 data showing non-inferior immunogenicity to the market leader Shingrix® for shingles, alongside a significantly improved tolerability profile. Curevo's strategy is to address vaccine hesitancy and accessibility issues, with plans to expand development into immunocompromised populations for chickenpox. The company is currently pre-revenue, advancing its lead candidate toward Phase 3 trials.

Therapeutic Areas